X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2759) 2759
Book Review (560) 560
Publication (219) 219
Book / eBook (49) 49
Book Chapter (18) 18
Newspaper Article (9) 9
Conference Proceeding (5) 5
Dissertation (4) 4
Magazine Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2592) 2592
index medicus (2586) 2586
male (1462) 1462
female (1281) 1281
middle aged (1134) 1134
aged (1031) 1031
bile duct neoplasms - drug therapy (784) 784
cancer (749) 749
bile duct neoplasms - pathology (732) 732
oncology (729) 729
cholangiocarcinoma (711) 711
adult (697) 697
gastroenterology & hepatology (639) 639
cholangiocarcinoma - pathology (587) 587
cholangiocarcinoma - drug therapy (579) 579
surgery (516) 516
animals (468) 468
chemotherapy (464) 464
treatment outcome (445) 445
bile ducts, intrahepatic (438) 438
aged, 80 and over (372) 372
prognosis (359) 359
bile ducts, intrahepatic - pathology (346) 346
cell line, tumor (340) 340
bile duct neoplasms - surgery (326) 326
liver (319) 319
retrospective studies (299) 299
bile duct neoplasms - metabolism (294) 294
medicine & public health (292) 292
cholangiocarcinoma - metabolism (279) 279
intrahepatic cholangiocarcinoma (277) 277
abridged index medicus (275) 275
antineoplastic combined chemotherapy protocols - therapeutic use (274) 274
tumors (267) 267
bile (264) 264
deoxycytidine - analogs & derivatives (264) 264
carcinoma (244) 244
bile duct neoplasms - mortality (243) 243
bile duct neoplasms - therapy (239) 239
gemcitabine (236) 236
survival (234) 234
cholangiocarcinoma - genetics (231) 231
risk factors (228) 228
bile duct neoplasms - genetics (227) 227
mice (227) 227
hepatocellular-carcinoma (226) 226
analysis (215) 215
neoplasm staging (214) 214
apoptosis (210) 210
cholangiocarcinoma - surgery (209) 209
liver neoplasms - drug therapy (209) 209
cholangiocarcinoma - mortality (198) 198
combined modality therapy (198) 198
expression (198) 198
survival rate (197) 197
bile duct neoplasms - diagnosis (194) 194
cholangiocarcinoma - therapy (187) 187
health aspects (186) 186
metastasis (186) 186
research (182) 182
antineoplastic agents - therapeutic use (178) 178
liver cancer (178) 178
care and treatment (171) 171
liver neoplasms - pathology (166) 166
fluorouracil - administration & dosage (165) 165
follow-up studies (165) 165
gastroenterology (164) 164
gastroenterology and hepatology (161) 161
hilar cholangiocarcinoma (159) 159
therapy (159) 159
management (155) 155
survival analysis (149) 149
deoxycytidine - administration & dosage (148) 148
immunohistochemistry (146) 146
pathology (145) 145
cholangiocarcinoma - diagnosis (144) 144
apoptosis - drug effects (143) 143
stents (143) 143
cell proliferation - drug effects (142) 142
adenocarcinoma - drug therapy (141) 141
tomography, x-ray computed (141) 141
diagnosis (140) 140
article (139) 139
chemotherapy, adjuvant (137) 137
patients (137) 137
radiology, nuclear medicine & medical imaging (137) 137
liver neoplasms - secondary (133) 133
primary sclerosing cholangitis (133) 133
radiotherapy (132) 132
time factors (130) 130
medical prognosis (127) 127
proteins (125) 125
cancer therapies (123) 123
disease-free survival (123) 123
gallbladder (122) 122
medicine (121) 121
pharmacology & pharmacy (119) 119
bile duct neoplasms - complications (117) 117
diagnosis, differential (117) 117
gallbladder neoplasms - drug therapy (116) 116
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2584) 2584
Japanese (149) 149
German (35) 35
French (23) 23
Spanish (11) 11
Russian (10) 10
Italian (8) 8
Chinese (6) 6
Danish (4) 4
Polish (4) 4
Korean (3) 3
Portuguese (2) 2
Czech (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 2017, Volume 23, Issue 12, pp. 1424 - 1435
Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a... 
MEDICINE, RESEARCH & EXPERIMENTAL | CHOLANGIOCARCINOMA | STEM-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | ESTABLISHMENT | GENOME | CELL BIOLOGY | HEPATOCELLULAR-CARCINOMA | IN-VITRO EXPANSION | ADULT LIVER | EXPRESSION | INACTIVATING MUTATIONS | Cell Proliferation | Primary Cell Culture - methods | Humans | Gene Expression Regulation, Neoplastic | Transcriptome | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - isolation & purification | Carcinoma, Hepatocellular - genetics | Liver Neoplasms - pathology | Bile Duct Neoplasms - genetics | Tumor Cells, Cultured | Bile Duct Neoplasms - drug therapy | Precision Medicine | Drug Screening Assays, Antitumor - methods | Organoids - pathology | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Mice, SCID | Xenograft Model Antitumor Assays | Cholangiocarcinoma - pathology | Animals | Cholangiocarcinoma - drug therapy | Carcinoma, Hepatocellular - pathology | Cholangiocarcinoma - genetics | Mice, Inbred NOD | Mice | Bile Duct Neoplasms - pathology | Cell culture | Liver cancer | Development and progression | Usage | Models | Research | Propagation | Liver | Hepatocellular carcinoma | Tissues | Drug screening | Metastases | Utilities | Biomedical materials | Organoids | Xenografts | Bioindicators | Cholangiocarcinoma | Extracellular signal-regulated kinase | Cultures | Pharmacology | Gene expression | Chemical compounds | Screening | Hepatocytes | Biomarkers | In vivo methods and tests | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2002, Volume 95, Issue 8, pp. 1685 - 1695
BACKGROUND. To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified. A... 
Adjuvant chemotherapy | Pancreatic carcinoma | Bile duct carcinoma | Disease-free survival | Carcinoma of the ampulla of Vater | Survival | Gallbladder carcinoma | BILIARY CARCINOMA | adjuvant chemotherapy | bile duct carcinoma | MITOMYCIN-C | ADENOCARCINOMA | survival | PANCREAS | P53 PROTEIN IMMUNOREACTIVITY | RADIATION-THERAPY | carcinoma of the ampulla of Vater | 5-FLUOROURACIL | EXTRAHEPATIC BILE-DUCT | CANCER-PATIENTS | pancreatic carcinoma | disease-free survival | ONCOLOGY | gallbladder carcinoma | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Common Bile Duct Neoplasms - drug therapy | Adult | Female | Common Bile Duct Neoplasms - surgery | Chemotherapy, Adjuvant | Mitomycins - administration & dosage | Bile Duct Neoplasms - drug therapy | Bile Duct Neoplasms - surgery | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Neoplasm Recurrence, Local | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Gallbladder Neoplasms - pathology | Bile Duct Neoplasms - pathology | Infusions, Intravenous | Common Bile Duct Neoplasms - pathology | Gallbladder Neoplasms - surgery | Evaluation | Drug therapy | Postoperative care | Gallbladder cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 574 - 581
The combination of gemcitabine and oxaliplatin with panitumumab versus gemcitabine and oxaliplatin alone has been evaluated in a phase 2, randomized trial as a... 
KRAS | panitumumab | biliary cancer | chemotherapy | cholangiocarcinoma | gemcitabine and oxaliplatin (GEMOX) | GROWTH-FACTOR-RECEPTOR | GALLBLADDER CANCER | OPEN-LABEL | II TRIAL | CAPECITABINE | ADVANCED CHOLANGIOCARCINOMA | CETUXIMAB | THERAPY | ONCOLOGY | Adenocarcinoma - pathology | Prognosis | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Male | Organoplatinum Compounds - administration & dosage | Adult | Female | Adenocarcinoma - genetics | Bile Duct Neoplasms - genetics | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Bile Ducts, Intrahepatic - pathology | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Treatment Outcome | Adenocarcinoma - drug therapy | Disease-Free Survival | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cholangiocarcinoma - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Bile Ducts, Extrahepatic - pathology | Gallbladder Neoplasms - pathology | Bile Duct Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Clinical trials | Usage | Dosage and administration | Gemcitabine | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 3/2011, Volume 18, Issue 3, pp. 651 - 658
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 4, pp. 1021 - 1031.e15
Background & Aims Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%−10% of primary liver cancers. We characterized its... 
Gastroenterology and Hepatology | CCA | Gene Expression | Hepatic | Genetic Analysis | SURVIVAL | INTRAHEPATIC CHOLANGIOCARCINOMA | PHASE-II | RECEPTOR | EXPRESSION PROFILES | BREAST-CANCER | BILIARY CANCER | LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | MUTATIONS | GASTROENTEROLOGY & HEPATOLOGY | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Proto-Oncogene Proteins p21(ras) | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Tumor Microenvironment | Male | Bile Duct Neoplasms - enzymology | Time Factors | Bile Duct Neoplasms - genetics | Cholangiocarcinoma - enzymology | Precision Medicine | Genetic Predisposition to Disease | Risk Assessment | Risk Factors | ras Proteins - antagonists & inhibitors | Survival Rate | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Phenotype | Belgium | Cell Line, Tumor | Cholangiocarcinoma - genetics | Mutation | Quinazolines - pharmacology | Trastuzumab | Cluster Analysis | Protein-Tyrosine Kinases - antagonists & inhibitors | ras Proteins - genetics | Prognosis | United States | Laser Capture Microdissection | Molecular Targeted Therapy | Patient Selection | Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacology | Bile Duct Neoplasms - drug therapy | Proto-Oncogene Proteins - antagonists & inhibitors | Bile Ducts, Intrahepatic - pathology | Cholangiocarcinoma - mortality | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | Proto-Oncogene Proteins - genetics | Chi-Square Distribution | Bile Ducts, Intrahepatic - enzymology | Cholangiocarcinoma - pathology | Cholangiocarcinoma - drug therapy | Proto-Oncogene Proteins B-raf - genetics | Bile Duct Neoplasms - mortality | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Bile Duct Neoplasms - pathology | Protein-Tyrosine Kinases - analysis | Queensland | Tyrosine | Genes | Amino acids | Transforming growth factors | Gene expression | Liver cancer | Epidermal growth factor | Analysis | Phenols | Genetic research | Genetic aspects | Health aspects | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 03/2018, Volume 148, Issue 3, pp. 507 - 514
Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with... 
Phase I | BRCA1/2 mutations | Veliparib | PARP inhibitor | Ovarian cancer | INTERGROUP TRIAL | FALLOPIAN-TUBE | BRCA 1/2 mutations | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | CELL LUNG-CANCER | BREAST-CANCER | RIBOSYLATION | GERMLINE BRCA1 | ONCOLOGY | ABT-888 | RECURRENT EPITHELIAL OVARIAN | PRIMARY PERITONEAL | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Ovarian Neoplasms - pathology | Induction Chemotherapy | Male | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Carcinoma, Hepatocellular - drug therapy | Benzimidazoles - administration & dosage | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Neutropenia - chemically induced | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Bile Duct Neoplasms - drug therapy | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Anemia - chemically induced | Carboplatin - administration & dosage | Treatment Outcome | Thrombocytopenia - chemically induced | Breast Neoplasms - drug therapy | Mesothelioma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Kidney Pelvis | Maximum Tolerated Dose | Breast Neoplasms - genetics | Carcinoma, Squamous Cell - drug therapy | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bayes Theorem | Carcinoma, Transitional Cell - drug therapy | Carcinoma, Basal Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 24, pp. 2617 - 2622
Journal Article
PLoS Genetics, ISSN 1553-7390, 02/2014, Volume 10, Issue 2, pp. e1004135 - e1004135
Author Summary Cholangiocarcinoma is a cancer that affects the bile ducts. Unfortunately, many patients diagnosed with cholangiocarcinoma have disease that... 
C-VIRUS-INFECTION | GROWTH-FACTOR RECEPTOR | BILIARY-TRACT CANCER | K-RAS MUTATIONS | RISK-FACTORS | GENETICS & HEREDITY | TUMOR-SUPPRESSOR GENE | HEPATITIS-C | PRIMARY SCLEROSING CHOLANGITIS | FLUKE-ASSOCIATED CHOLANGIOCARCINOMA | NEGATIVE BREAST-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Prognosis | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Transcriptome | Imidazoles - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | Pyridazines - administration & dosage | Quinazolines - administration & dosage | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Bile Ducts, Intrahepatic - pathology | Pyrimidines - administration & dosage | Signal Transduction - genetics | Cholangiocarcinoma - pathology | Protein Kinase Inhibitors | Cholangiocarcinoma - drug therapy | Cell Line, Tumor | Cholangiocarcinoma - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Bile Duct Neoplasms - pathology | Mutation | Genome, Human | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Sulfonamides - administration & dosage | Antimitotic agents | Analysis | Genomics | Research | Antineoplastic agents | Health aspects | Tumors | Index Medicus | Studies | Hepatitis | Substance abuse treatment | Genetic engineering | Genomes | Kinases | Gene expression | Patients | Cancer
Journal Article